Nivolumab keeps HCC in check and opens avenues for checkmate – Nature.com
|
Nivolumab keeps HCC in check and opens avenues for checkmate
Nature.com New data indicate the therapeutic potential of immunotherapy with the anti-PD-1 antibody nivolumab in this disease. In the phase I/II CheckMate 040 trial, 262 patients with advanced-stage HCC were treated with nivolumab; 76% had received prior systemic … |
